Updates are available Correction dated 2023-02-07
Click to view Correction: https://doi.org/10.1038/s41408-023-00793-y
-
Authors
Kurata, Keiji https://orcid.org/0000-0003-1060-9218
James-Bott, Anna https://orcid.org/0000-0001-9658-5354
Tye, Mark A.
Yamamoto, Leona
Samur, Mehmet K. https://orcid.org/0000-0002-9978-5682
Tai, Yu-Tzu https://orcid.org/0000-0001-6199-3569
Dunford, James https://orcid.org/0000-0002-9932-4042
Johansson, Catrine
Senbabaoglu, Filiz
Philpott, Martin
Palmer, Charlotte
Ramasamy, Karthik
Gooding, Sarah
Smilova, Mihaela
Gaeta, Giorgia
Guo, Manman
Christianson, John C.
Payne, N. Connor https://orcid.org/0000-0001-9513-6194
Singh, Kritika
Karagoz, Kubra
Stokes, Matthew E.
Ortiz, Maria
Hagner, Patrick
Thakurta, Anjan
Cribbs, Adam
Mazitschek, Ralph
Hideshima, Teru
Anderson, Kenneth C. https://orcid.org/0000-0002-6418-0886
Oppermann, Udo
-
Funding
Funding for this research was provided by:
Stuchin Family Fellowship, Vicki and Neal Roth Fellowship for Multiple Myeloma Research
EPSRC Oxford DTC DPhil fellowship
BMS-Oxford fellowship
Cancer Research UK
National Science Foundation Graduate Research Fellowship,
M.R.C career development fellowship
U.S. Department of Health & Human Services | National Institutes of Health (R21AI13298, R01AI143723, R01-CA178264, SPORE-P50100707, R01-CA050947, R01-CA178264, P01-155258)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
National Natural Science Foundation of China (81800204)
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, Riney Family Myeloma Initiative
Bone Cancer Research Trust
Rosetrees Trust
Chordoma Foundation
LEAN program grant of the Leducq Foundation
- License Information
-
More Information
Article History
Received: 4 October 2022
Revised: 23 December 2022
Accepted: 5 January 2023
First Online: 12 January 2023
Change Date: 2 February 2023
Change Type: Update
Change Details: The name of Anna James-Bott has been corrected.
Competing interests
: KKurata, AJB, MAT, LY, MKS, YTT, JD, CJ, FS, MP, KR, SG, MS, GG, MG, CP, JCC, KS, AC, TH have no competing interests relevant to this work. KCA is an American Cancer Society Clinical Research Professor; an advisor for Pfizer, Amgen, AstraZeneca, Janssen, and Precision Biosciences; and board member with equity interests in C4 Therapeutics, Dynamic Cell Therapies, NextRNA, Window, And Starton therapeutics. RM is a scientific advisory board (SAB) member and equity holder of Regenacy Pharmaceuticals, ERX Pharmaceuticals, and Frequency Therapeutics. MAT, NCP, and RM are inventors on patent applications related to this work. KKaragoz, MO, MS, PH and AT are employees and shareholders of Bristol Myers Squibb.
